Praomys (Mastomys) natalensis: a model for gastric carcinoid formation. by Nilsson, O. et al.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 65 (1992), 741-751
Praomys (Mastomys) natalensis:
A Model for Gastric Carcinoid Formation
OLA NILSSON, M.D., Ph.D., BO WANGBERG, M.D., LENA JOHANSSON,
IRVIN M. MODLIN, M.D. Ph.D., AND HAKAN AHLMAN, M.D., Ph.D.
Department ofHistology, University ofGoteborg, DepartmentofSurgery, Sahlgrenska
Hospital, Goteborg, Sweden, andDepartmentofSurgery, Yale University Schoolof
Medicine, NewHaven, Connecticut
Received July 13, 1992
The gastric carcinoid tumors of Praomys (Mastomys) natalensis have been reviewed with
respect to histogenesis, development, biochemistry, and morphological properties. Multi-
centric gastric carcinoids frequently develop in the oxyntic mucosa of aging Mastomys. The
development ofthese tumors can be significantly enhanced bydrug-induced hypergastrinemia,
e.g., histamine2-receptor blockade. Spontaneous and drug-induced gastric carcinoids are
endocrine in nature, as evidenced bytheir argyrophilic stainingproperties and chromogranin A
content. They are also rich in histidine decarboxylase activity and produce large amounts of
histamine, although other hormones, such as peptide YY and enteroglucagon, have also been
demonstrated in these tumors. Ultrastructurally, gastriccarcinoids are composed oftumorcells
with typical secretory granules resembling those ofenterochromaffin-like (ECL) cells. A close
examination of the gastric carcinoids in Mastomys reveals striking similarities with gastric
carcinoids developing in humans suffering from chronic atrophic gastritis type A or from the
Zollinger-Ellison syndrome in combination with multiple endocrine neoplasia type 1 (MEN-1).
Both these conditions are associated with hypergastrinemia and a higher risk for developing
multi-centric gastric carcinoids of ECL-cell origin. The Mastomys tumor model therefore
appears to be a significant experimental model in which induction and formation of gastric
carcinoid tumors can be studied.
INTRODUCTION
The diagnosis and management ofgastric carcinoid tumors hasbeen the subject of
much debate overtheyears [1-10]. Gastric carcinoids in man mayoccursporadically,
but they frequently arise in patients with chronic atrophic gastritis ofthe non-antral
mucosa (CAG type A) [11-13]. Patients with the Zollinger-Ellison syndrome and
multiple endocrine neoplasia type 1 (MEN-1) also have a greater risk ofdeveloping
gastric carcinoids [14]. A common feature in these two groups of patients is
prolonged hypergastrinemia. It has therefore been suggested that achlorhydria or
excessive production of gastrin from a gastrinoma will cause hypergastrinemia,
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leading to hyperplasia of the gastric enterochromaffin-like (ECL) cells and to
formation ofgastric carcinoids [15-17]. Although vigorously challenged [18,19], this
hypothesis has prompted experimental studies to elucidate the mechanisms regulat-
ingECL-cell growth. Apowerful tool in ECL-cell researchbecame availablewith the
introduction of potent inhibitors of gastric acid secretion, i.e., histamine2-receptor
blockers and proton pump inhibitors. These drugs induce sustained hypergas-
trinemia and cause proliferation ofgastric ECLcells, which, after lifelong treatment
ofexperimental animals, maytransform into gastric carcinoids [20-22].
Experimental studies on gastric ECL-cell growth and carcinoid formation have
been performed primarily in rodents. The earliest studies utilized the African rodent
Praomys (Mastomys) natalensis, which is prone to develop spontaneous gastric
carcinoids in the oxyntic mucosa [23]. Later studies on ECL-cell growth were carried
out in rats and mice,where gastric carcinoids developed afterlifelongtreatmentwith
potent inhibitors of acid secretion [20-22]. In recent years, the interest in gastric
carcinoids of Mastomys has been renewed because it was shown that carcinoid
tumors develop very rapidly in this species duringhistamine2-receptor blockade [24].
This review will focus on the biology of the Mastomys gastric carcinoids and discuss
the relevance ofthis tumor model in relation to the human situation.
HISTORICAL ASPECTS
Praomys (Mastomys) natalensis or "the multimammate mouse" is one of the most
common wild rodents in Africa and plays an important role in the natural cycle of
several zoonoses [25]. It has been widely used in laboratories as a vector for diseases
such as plague, Lassa fever, and bilharzia; however, a high incidence of gastric
tumors was noted in a laboratory strain ofMastomys in the late 1950s [26]. Gastric
tumors and mucosal hypertrophy were observed in 40 percent of Mastomys dying
from natural causes. These gastric tumors were initially characterized as adenocarci-
nomas but were later shown to possess endocrine features and were thus reclassified
as gastric carcinoids [23]. In addition to gastric carcinoids, Mastomys may also
develop tumors invariousotherorgans, includingliver, spleen, thymus, pituitary, and
adrenals [27]. The incidence of gastric carcinoids increases with age and has been
reported to be as high as 40-60 percent in Mastomys 12-24 months of age [27,28].
The malignant potential of gastric carcinoids was soon recognized, as well as the
capacity ofthese tumors to grow after transplantation to otherMastomys or to nude
mice [23,29-33]. Transplantation of carcinoid tumors for several generations has
generated different substrainsoftumorswithdistinct differences in hormoneproduc-
tion [31-33]. Inbreeding ofMastomys has created two different strains, designated Y
and Z. The Z strain develops spontaneous antral adenocarcinomas and fundic
carcinoids, while the Y strain, like the wild type, develops only fundic carcinoids
[34-36]. Subsequent studies in Mastomys have been focused either on gastric
carcinoids or on gastric adenocarcinomas [36,37]. The following sections will exam-
ine the gastric carcinoid tumors inMastomys and describe some important character-
istics ofthese tumors.
CARCINOID TUMOR IN AL4STOMYS
Hormone Production
Gastric carcinoids in Mastomys secrete a variety of amine and peptide hormones.
Histamine, as well as the histamine-synthesizing enzyme histidine decarboxylase
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(HDC), can be demonstrated in tumor extracts [31,38-41]. Tumor-bearing animals
have elevated levels of histamine in peripheral blood and an increased urinary
excretion of histamine [30,31]. Excessive production of histamine from gastric
carcinoids may induce acid hypersecretion and cause severe gastric or duodenal
ulceration in tumor-bearing animals [29]. There is also evidence that some gastric
carcinoids, and subtypes thereof, may produce serotonin. The A- and E-lines of
transplantable gastric carcinoids described by Hosoda et al. [30-33] contain signifi-
cant amounts of serotonin and tryptophan hydroxylase, the enzyme converting
tryptophan to the serotonin precursor, 5-hydroxytryptophan. Blood levels of seroto-
nin as well as urinary excretion of 5-hydroxyindole acetic acid (5-HIAA) are also
elevated in animals transplanted with the A- or E-line tumors. Tumor-bearing
animals may also show typical carcinoidvasoreactions uponprovocationwithvolatile
anesthetics [32].
Assayofpeptide hormones has demonstratedlarge amountsofpeptide YY (PYY)
and enteroglucagon (EG) in gastric carcinoid tumors ofhypergastrinemicMastomys
[24,42]. Plasma levels of PYY and EG were also consistently elevated in tumor-
bearing animals. Otherpeptide hormones, i.e.,gastrin, somatostatin, bombesin, VIP,
pancreatic polypeptide, gastric inhibitorypolypeptide, secretin, and CCK-8 were not
detectable in tumor extracts.
Morphological Characteristics
Gastric carcinoids inMastomys are located in the acid-producing (oxyntic) part of
the gastric mucosa. Gross lesions appear as multiple elevated nodules, frequently
with a central ulceration, and a major submucosal tumor mass [28]. In the early
Mastomys colonies, carcinoid tumors were shown to have a malignant potential with
metastatic growth in regional lymph nodes and liver in approximately one-fourth of
the tumor-bearing animals [23,28]. Microscopic examination of gross tumors re-
vealed submucous nodules with neoplastic cells in trabecular or adenoid patterns.
The surrounding gastric mucosa was usually hyperplastic. Intramucosal carcinoids
(microcarcinoids), however, were frequently observed in macroscopically normal
mucosa. The endocrine nature of tumors was demonstrated by the argyrophil
reactions of Sevier-Munger or Grimelius [23,28,29,40,41,43]. Hyperplastic lesions
usually had a strong argyrophilia, while dysplastic and neoplastic lesions displayed a
weaker argyrophil reaction. The tumor cells belonged to the APUD family of
endocrine cells [44], since they had the capacity to take up and decarboxylate amine
precursors [40]. Immunocytochemical studies demonstrated chromogranin A in a
majority of tumor cells, confirming the endocrine nature of the tumors [41]. A
majority of tumor cells was labeled by antisera against histamine, while no labeling
was obtained with antisera against gastrin, somatostatin, serotonin, or bombesin
[41,45]. Aminorpopulation oftumorcells in hypergastrinemicMastomys waslabeled
by PYY andenteroglucagon antisera [43,46], indicatingbiochemical heterogeneityof
tumor cells. Ultrastructural analysis of carcinoid tumors confirmed the endocrine
nature of these tumors and demonstrated specific secretory granules in tumor cells
[24,28,40,46,47]. The number of granules in each tumor cell was usually lower than
that observed in normal gastric endocrine cells, and some tumor cells even lacked
secretory granules. The tumor cell granules were characterized by an electron-dense
core surrounded by a limiting membrane. Avariety ofstructurally distinct secretory
granules have been described, which may reflect biochemical or functional differ-
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ences among tumor cells. In hypergastrinemic Mastomys, tumor cell granules were
commonlyofthevesicular type, similar to those observed in normalgastricECLcells
[48] (Fig. 1).
Histogenesis ofTumors
The morphological changes occurring in the gastric mucosa ofMastomys prior to
the formation of spontaneous carcinoids have been examined by Soga et al. [43].
They have classified the proliferative changes in the endocrine cell population ofthe
fundic mucosa into three stages. During stage I (hyperplastic), proliferation of
endocrine cells takes place within the basal part of the gastric glands and comprises
an increased number ofendocrine cells, occasionally formingchains. During stage II
(pre-neoplastic), endocrine cells form larger nodules, which are still contained
within the gastric glands. During stage III (neoplastic), endocrine cells grow outside
the glands in the lamina propria and eventually form larger masses (micro- and
macrocarcinoids). These changes are multi-focal and occur in all parts ofthe fundic
mucosa. No changes are observed among the endocrine cells of the antral mucosa
[43].
The speed by which gastric endocrine lesions develop inMastomys can be greatly
enhanced by histamine2-receptor blockade [24]. This fact has facilitated the detailed
analysis ofgastric carcinoid formation in this species. The sequential development of
hyperplastic, dysplastic, and neoplastic ECL-cell lesions during insurmountable
histamine2-receptor blockade by loxtidine have been described [41]. The histopatho-
logical classification system described by Solcia et al. [49] for gastric non-antral
endocrine growths was used in these studies. Although this classification system was
originally developed to describe endocrine cell lesions in the oxyntic mucosa ofman,
it has proved to be useful and accurate when describing endocrine cell proliferation
in the oxyntic mucosa of Mastomys. Loxtidine treatment for eight weeks caused a
marked hyperplasia of ECL cell. The hyperplasia was "diffuse" (simple) and
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FIG. 2. Proliferatinggastricendocrine
cells in hypergastrinemic Mastomys (lox-
tidine-treated). A. In normaloxyntic
mucosa, endocrine cells are scattered in
the lower halfofthegastricglands(con-
trol animal). B,C. During loxtidine
treatment, endocrine cells in theoxyntic
mucosa increase in number and form
chains (linear hyperplasia, arrows, B) or
mirndules (C). Immunoperoxidase
stainingusinghistamine antibodies(A,C)
5 * =J or chromogranin antibodies (B). Bars
--- - j " indicate 50Am (A) or 20Fm (B,C).
characterized by an increase in the ECL-cell density (100 percent above normal
controls), while typical linear or nodular hyperplasia was rare. After 16 weeks of
treatment, there was amarked ECL-cell hyperplasia, which wascharacterizedbythe
formation of numerous chains and micronodules of endocrine cells (Fig. 2). At this
point, dysplastic lesions, e.g., microinvasive growth or enlarging micronodules,
appeared in some animals. Extensive growth ofdysplastic lesions of endocrine cells
was observed after 24 and 32weeks oftreatment, particularly in the basal part ofthe
gastric mucosa. Micro- and macrocarcinoids were also present in one-fourth to
one-third of the animals at this point (Fig. 3). Histamine concentrations and HDC
activity in the fundic mucosa increased gradually during histamine2-receptor block-NILSSON ET AL.
FIG. 3. Proliferating gastric endocrine cells in hypergastrinemic Mastomys (loxtidine-treated). A.
Endocrine cells are growing outside the gastric epithelium (microinvasive growth) (arrows). B. Fusing
micronodules are forming a microcarcinoid. Immunoperoxidase staining using chromogranin antibodies.
Bars indicate 20 p.m.
ade in parallel with the endocrine cell proliferation. The gradual accumulation of
hyperplastic, dysplastic, and neoplastic changes over time suggests that carcinoid
tumors develop from hyperplastic and dysplastic lesions [41]. Similar, although less
pronounced, changes in the gastric endocrine cell population ofMastomys have been
observed after proton pump inhibition [50].
The factors responsible for the development ofgastric carcinoids inMastomys are
poorly understood. The genetic defects inMastomys that make this species suscepti-
ble to tumor development are unknown. The rapid induction of gastric carcinoids
during histamine2-receptor blockade-induced hypergastrinemia suggest, however,
that gastrin may act as a promoter oftumor growth. This assumption is supported by
the fact that gastrin/CCK receptors are abundant on tumor cell membranes from
Mastomys gastric carcinoids [51,52]; however, the mechanisms regulating ECL-cell
growth have primarily been studied in other species, e.g., in the rat. In this species,
hypergastrinemia induced pharmacologically by inhibition of acid secretion, surgi-
cally by partial corpectomy, or by direct infusion of gastrin stimulates the self-
replication rate of ECL cells [53-57]. This process leads to an increased mucosal
thickness and ECL-cell density. In the rat, these changes are reversible after
short-term (ten weeks) hypergastrinemia [53]; however, life-long (>1.5 years)
inhibition of acid secretion or partial corpectomy in rats eventually leads to forma-
tion of gastric carcinoids [20-22,55]. From these studies, it is evident that gastrin
plays an important role in the generation ofECL-cell tumors, although the exact role
ofgastrin in the transformation of ECL cells remains to be elucidated. It is possible
that gastrin stimulates ECL-cell proliferation directly by activating gastrin/CCK
receptors on the ECL cell, but it may also be that gastrin exerts its trophic action
indirectly by stimulating local production of growth factors, e.g., epidermal growth
factor or transforming growth factor alpha.
Hypergastrinemia induced by acid inhibition also produces changes in the antral
endocrine cell population of the rat. The number of antral G cells increases during
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omeprazole treatment,while the numberofD cells decreases. The result is amarked
increase in the G/D cell ratio in the antral mucosa [58]. Somatostatin receptor
expression is abundant in the gastrointestinal tract as well as in gut neuroendocrine
tumors [52,59,60]. The decrease in antral D cells and somatostatin contentsobserved
during omeprazole treatment may therefore imply a downregulation ofmechanisms
inhibitory for ECL-cell growth. The proliferation ofECL cells may therefore be the
consequence ofan imbalancebetween factorsstimulatinggrowth andfactorsinhibit-
ing ECL-cell growth. Our knowledge about these factors is still limited and will be
the focus offuture research.
Relevance ofthe Mastomys TumorModel
The relevance of the Mastomys tumor model to human gastric carcinoids is
dependent on the extent to which theMastomys gastric carcinoids share the biologi-
cal properties oftheir human counterparts. Gastric carcinoids in man can be divided
into two groups: (1) multiple small tumors (predominantly composed of ECL cells)
associated with hypergastrinemia and chronic atrophic gastritis (CAG) type A or
Zollinger-Ellison syndrome and MEN-1 [12,61,62] and (2) solitary tumors occurring
sporadically and not associated with hypergastrinemia. The solitary gastric carci-
noids within the fundus corpus were first believed to be rare (3 percent of all
gastrointestinal carcinoids) butmayactuallybe morefrequent (31 percent) (Solcia et
al. in this symposium). They are not dependent on hypergastrinemia and have a high
metastatic potential (55 percent), including distant metastases [62]. The multi-
centric carcinoids associated with hypergastrinemia are usually small and located
within the fundus corpus. They have a low tendency to metastasize, mainly to
regional lymph nodes (6-22 percent) [6,11,61,63]. The multi-centric gastric carci-
noids in man thus have several features in common with spontaneous and drug-
induced carcinoids in Mastomys. Sporadic gastric carcinoids in man, on the other
hand, are invariablysolitary tumors located in the fundus/corpus region and are thus
distinctly different from the gastric carcinoids inMastomys.
Morphologically, human andMastomyscarcinoid tumors alsodisplaygreat similar-
ities. All gastric carcinoids in man and inMastomys are invariably argyrophilic when
stained with the Grimelius technique and immunopositive when stained with anti-
sera against chromogranin A [11-13]. The Masson silver reaction is usuallynegative,
but small numbers of serotonin-, gastrin-, somatostatin-, or pancreatic polypeptide
immunoreactive tumor cells have been reported to occur in human gastric carci-
noids, while gastric carcinoids in Mastomys have been shown to contain a small
population of peptide YY (PYY) and enteroglucagon storing cells [12,13,24,61].
Ultrastructurally, human gastric carcinoids are predominantly made up ofECL cells
with typical secretory granules. A variable number of other gastric endocrine cells,
e.g., EC, D, X, P, G, and PP cells, may also be found [12,13]. Ultrastructural analysis
ofcarcinoid tumors inMastomys has also demonstrated that a majority ofthe tumor
cells are of ECL-cell type, although other cell types may also be encountered
[24,28,40,46,47] (Fig. 1). Biochemical identification of the hormonal contents of
human gastric carcinoids has been incomplete, but there are reports demonstrating
histamine production by tumors aswell as increasedurinaryexcretion ofmethylimid-
azole acetic acid (MeImAA), a major metabolite ofhistamine [7,8,64]. The method-
ological difficulties involved in the histochemical or immunohistochemical
demonstration of histamine [65] may suggest that the frequency of histamine-
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producing human gastric carcinoids may have been underestimated. Gastric carci-
noids inMastomys, on the other hand, regularlyproduce large amounts ofhistamine,
which may be responsible for such symptoms as flushing and gastric/duodenal
ulceration. Patients with CAG type A or Zollinger-Ellison with MEN-1 and gastric
carcinoids have characteristic "precursorlesions" inthe non-tumoral gastricmucosa.
Such precursor lesions include hyperplasia and dysplasia of gastric endocrine cells,
e.g., linear, micronodular, or microinvasive growth [13,49]. The same characteristic
growth patterns are also observed among gastric endocrine cells in Mastomys
subjected to long-term treatment with histamine2-receptor blockers [41], which
points to similarities in histogenesis ofthese tumors. The structural and biochemical
similarities between human andMastomys gastric carcinoids thus suggest a common
histogenesis with transformation of ECL cells into gastric carcinoids during pro-
longed hypergastrinemia.
The importance ofhypergastrinemia for the development ofgastric carcinoids has
led to experimentation with the surgical treatment of these patients. The multi-
centric carcinoids were initially treated with total gastrectomy, but, if gastrin is a
crucial growth factor for these tumors, a lesser surgical procedure, e.g., antrectomy,
would be adequate treatment to reverse the hyperplasia of the ECL-cell system
[3,8,66]. Spontaneous resolution of two cases has been reported [2]. Recently, rapid
regression of ECL-cell carcinoids following antrectomy was reported in three
patients with pernicious anemia [10]. Urinary excretion of MeImAA, the main
histamine metabolite, may serve as a tumor marker for gastric carcinoids: slightly
elevated levels were seen in patients with ECL-cell tumors, while the tumor burden
in gastric carcinoids of the sporadic type was well reflected by the MeImAA levels
[67]. These tumors also have a deficiency of aromatic amino acid decarboxylase,
leading to excessive secretion of5-HTP and secondarilyhigh 5-HIAAexcretion after
synthesis of5-HT and degradation in the kidneys.
CONCLUSION
Gastric carcinoid tumors ofMastomys share several morphological and biochemi-
cal features with human gastric carcinoids. In man, different types of gastric
carcinoid exist; especially those occurring in patientswith CAG type A or Zollinger-
Ellison syndrome with MEN-1 show similarities with the Mastomys tumors. Distinc-
tive properties such as argyrophilia, chromogranin A, and typical secretory granules
as well as characteristic precursor lesions suggest that a majority of these tumors
originate from gastric ECL cells. Furthermore, there appear to be common mecha-
nisms in the pathogenesisofthese tumors. Hypergastrinemia invariably accompanies
gastric carcinoids in patients with CAG type A and Zollinger-Ellison syndrome with
MEN-1, suggesting an important role forgastrin in the development ofthese tumors.
Experimentallyinduced hypergastrinemia, e.g., byhistamine2-receptorblockade, has
also been shown to increase the development of carcinoid tumor in Mastomys.
Against this background, it is of utmost importance to take advantage of the
Mastomys model in order to elucidate the cellular mechanisms responsible for the
proliferation of gastric endocrine cells. In addition, the Mastomys model can be
utilized to perform reversibility studies, using chronic treatment with potent gastric
acid inhibitors, and to study if reversal of endocrine cell hyperplasia, or even of
dysplasia/neoplasia, may occur after cessation oftreatment.
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